Rani Therapeutics Holdings (RANI) Other Non-Current Assets (2021 - 2026)
Rani Therapeutics Holdings (RANI) posted Other Non-Current Assets of $246000.0 for Q2 2026, little changed on a QoQ basis from $246000.0 in Q1 2026, and down 16.04% year-over-year from $293000.0 in Q2 2025.
Analysis
Rani Therapeutics Holdings (RANI) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Rani Therapeutics Holdings has reported Other Non-Current Assets for 6 years, with the latest figure at $246000.0 in Q2 2026.
- On a quarterly basis, Other Non-Current Assets fell 16.04% year-over-year to $246000.0 in Q2 2026; TTM through Jun 2026 was $246000.0, a 16.04% decrease from a year earlier, with the FY2025 full-year figure at $246000.0, changed 0.0% from the prior year.
- Other Non-Current Assets was $246000.0 for Q2 2026 at Rani Therapeutics Holdings, roughly flat from $246000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $500000.0 in Q3 2022, with the low at $245000.0 in Q3 2025.
- Average Other Non-Current Assets over 5 years is $271000.0, with a median of $246000.0 recorded in 2023.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets gained 19.11% in 2025, then decreased 16.04% in 2026.
- Over 5 years, Other Non-Current Assets stood at $500000.0 in 2022, then slumped by 50.8% to $246000.0 in 2023, then changed by 0.0% to $246000.0 in 2024, then changed by 0.0% to $246000.0 in 2025, then changed by 0.0% to $246000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $246000.0 (Q2 2026), $246000.0 (Q1 2026), and $246000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - | 246,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 246,000.00 |
| Mar 31, 2026 | 246,000.00 |
| Dec 31, 2025 | 246,000.00 |
| Sep 30, 2025 | 245,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Mar 31, 2025 | 246,000.00 |
| Dec 31, 2024 | 246,000.00 |
| Sep 30, 2024 | 246,000.00 |
| Jun 30, 2024 | 246,000.00 |
| Mar 31, 2024 | 246,000.00 |
| Dec 31, 2023 | 246,000.00 |
| Sep 30, 2022 | 500,000.00 |
| Jun 30, 2021 | 3.41 Mn |